From conference call ,in question period most analysis were giving congrats to strong quarter which they met.   Appears pipleline for future orders is strong with more approvals on the way. Nothing in conference call to be concerned with. Company is meeting expectations & with any  FDA approvals could boost revenues significantly down the road.